Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pyrexia, Vaccination site erythema, Vaccination site pain
Clinical narrative: Severe malaise/feeling sick present with significant interference with activity; Joint pain with some interference with activity; Severe muscle pain significantly interfering with activity; Moderate fever; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Severe fatigue with significant interference with activity; Headache that interfered with activity OR required repeated use of a nonprescription pain reliever; Mild injection site swelling; Mild injection site redness; Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement); This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Severe malaise/feeling sick present with significant interference with activity), ARTHRALGIA (Joint pain with some interference with activity), MYALGIA (Severe muscle pain significantly interfering with activity), PYREXIA (Moderate fever) and VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In January 2024, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In January 2024, the patient experienced MALAISE (Severe malaise/feeling sick present with significant interference with activity), ARTHRALGIA (Joint pain with some interference with activity), MYALGIA (Severe muscle pain significantly interfering with activity), PYREXIA (Moderate fever), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), FATIGUE (Severe fatigue with significant interference with activity), HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever), VACCINATION SITE SWELLING (Mild injection site swelling), VACCINATION SITE ERYTHEMA (Mild injection site redness) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)). At the time of the report, MALAISE (Severe malaise/feeling sick present with significant interference with activity), ARTHRALGIA (Joint pain with some interference with activity), MYALGIA (Severe muscle pain significantly interfering with activity), PYREXIA (Moderate fever), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), FATIGUE (Severe fatigue with significant interference with activity), HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever), VACCINATION SITE SWELLING (Mild injection site swelling), VACCINATION SITE ERYTHEMA (Mild injection site redness) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2024, Body temperature: 101.3 to 102 °F, Moderate fever.        Concomitant medication was not provided. The patient experienced events anytime during the 2 days after COVID-19 vaccination, which occurred on 26-Jan-2024 and 27-Jan-2024. Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-759560 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-759560:Same reporter, Master case